Evidence map›Paper›PMID 36793600›Full record

ReviewFrontiers in oncology2023

DNA repair deficiency as circulating biomarker in prostate cancer.

Martina Catalano, Daniele Generali, Marta Gatti, Barbara Riboli, Leda Paganini, Gabriella Nesi, Giandomenico Roviello

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Liquid biopsy to personalize treatment for metastatic prostate cancer.American journal of translational research · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Martina CatalanoSchool of Human Health Sciences, University of Florence, Florence, Italy.
Daniele GeneraliDepartment of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital Trieste, Trieste, Italy.
Marta GattiServizio di Citogenetica e Genetica - Azienda Socio-Sanitaria Territoriale (ASST) di Cremona, Cremona, Italy.
Barbara RiboliServizio di Citogenetica e Genetica - Azienda Socio-Sanitaria Territoriale (ASST) di Cremona, Cremona, Italy.
Leda PaganiniServizio di Citogenetica e Genetica - Azienda Socio-Sanitaria Territoriale (ASST) di Cremona, Cremona, Italy.
Gabriella NesiDepartment of Health Sciences, University of Florence, Florence, Italy.
Giandomenico RovielloDepartment of Health Sciences, University of Florence, Florence, Italy.
Istituti Ospitalieri di Cremona · ITUniversity of Florence · ITOspedale di Cattinara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deleterious aberrations in DNA repair genes are actionable in approximately 25% of metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination repair (HRR) is the DNA damage repair (DDR) mechanism most frequently altered in prostate cancer; of note

Indexed as

circulating biomarkercirculating tumor DNADNA damage repairliquid biopsyprostate cancer

Identifiers

PMID36793600
PMCPMC9922904
OpenAlexW4318465568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.